Titan Pharmaceuticals, Inc. (TTNP) quarterly cash flow statement — complete operating, investing & financing history
| Cash from Operations | -680K | -867K | -506K | -693K | -2.07M | -613K | -2.25M | -1.83M | -1.11M | -1.9M | -1.58M | -1.87M |
| Operating CF Margin % | - | - | -5060% | - | - | - | -2772.84% | -45875% | -111200% | -1937.76% | -3096.08% | -46825% |
| Operating CF Growth % | 67.12% | -41.44% | 77.47% | 62.23% | -85.97% | 67.72% | -42.24% | 2.03% | 37.07% | 35.93% | -46.07% | 17.2% |
| Net Income | -689K | -563K | -790K | -763K | -2.09M | -1.06M | -1.97M | -338K | -1.59M | -1.68M | -2.57M | -2.64M |
| Depreciation & Amortization | 0 | 0 | 0 | 0 | 3K | 2K | 3K | 27K | 39K | 43K | 45K | 48K |
| Stock-Based Compensation | 0 | 0 | 0 | 0 | 0 | 0 | 48K | 411K | 264K | 290K | -91K | 541K |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | -166K | -1.21M | -309K | -428K | 0 | 0 |
| Other Non-Cash Items | 0 | 0 | 0 | 0 | -1K | -1K | 167K | -523K | 309K | 428K | 450K | 295K |
| Working Capital Changes | 9K | -304K | 284K | 70K | 23K | 446K | -328K | -202K | 171K | -557K | 583K | 176K |
| Change in Receivables | 0 | 0 | 52K | -14K | 95K | 913K | -10K | -18K | 0 | 18K | 13K | 52K |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | -18K | 18K | 0 | 0 | 354K | 9K |
| Change in Payables | 25K | -9K | -168K | 15K | -14K | 22K | -102K | -337K | 33K | -70K | -569K | 181K |
| Cash from Investing | 0 | 0 | 0 | 0 | 0 | 0 | 504K | 228K | 0 | 0 | 0 | 0 |
| Capital Expenditures | 0 | 0 | 0 | 0 | 0 | 0 | -2K | 0 | 0 | 0 | 0 | 0 |
| CapEx % of Revenue | - | - | - | - | - | - | 2.47% | - | - | - | - | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 506K | 228K | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 | 0 | 0 | 506K | 228K | 0 | 0 | 0 | 0 |
| Cash from Financing | 1.54M | -19K | -62K | 0 | 0 | 0 | 406K | 9.59M | 0 | 0 | 0 | 0 |
| Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Equity Issued (Net) | 1000K | 0 | 0 | 0 | 0 | 0 | 406K | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | -62K | -19K | -62K | 0 | 0 | 0 | 0 | 9.59M | 0 | 0 | 0 | 0 |
| Net Change in Cash | 858K | -886K | -568K | -693K | -2.07M | -614K | -1.34M | 7.99M | -1.11M | -1.9M | -1.58M | -1.87M |
| Free Cash Flow | -680K | -867K | -506K | -693K | -2.07M | -613K | -2.25M | -1.83M | -1.11M | -1.9M | -1.58M | -1.87M |
| FCF Margin % | - | - | -5060% | - | - | - | -2775.31% | -45875% | -111200% | -1937.76% | -3096.08% | -46825% |
| FCF Growth % | 67.12% | -41.44% | 77.49% | 62.23% | -85.97% | 67.72% | -42.37% | 2.03% | 37.07% | 35.93% | -45.4% | 17.2% |
| FCF per Share | -0.64 | -0.95 | -0.56 | -0.76 | -2.26 | -0.72 | -2.88 | -2.44 | -1.48 | -2.53 | -2.22 | -2.56 |
| FCF Conversion (FCF/Net Income) | 0.99x | 1.54x | 0.64x | 0.91x | 0.99x | 0.58x | 1.14x | 5.43x | 0.70x | 1.15x | 0.62x | 0.71x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 13K | 17K | 4K | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |